Tasly Pharmaceuticals (SHA: 600535), a leading pharmaceutical company in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to proceed with a clinical study for its human umbilical cord mesenchymal stem cell injection, B2278. The study aims to evaluate the efficacy of this therapy in patients with chronic heart failure resulting from chronic ischemic cardiomyopathy who are indicated for coronary artery bypass grafting (CABG).
B2278, initially developed by Shanghai East Hospital, was licensed to Tasly in August 2022, with the agreement covering global regulatory filing and clinical development for the Class 3A hospital’s innovation. Preclinical research has indicated that B2278 possesses the ability to modulate the microenvironment of myocardial tissue through paracrine actions, significantly reducing tissue damage in ischemic cardiomyopathy, enhancing heart function in animal models, stimulating vascular regeneration, and decreasing myocardial apoptosis.- Flcube.com
